
News|Articles|January 1, 2004
Docetaxel/platinum combinations are efficacious in treatment of NSCLC
A regimen of docetaxel and cisplatin offers better survival and response rates than a combination of vinorelbine and cisplatin in the treatment of advanced non-small-cell lung cancer, according to a phase 3 study published in the online version of the Journal of Clinical Oncology. In addition, the findings demonstrated that docetaxel is as effective as vinorelbine/cisplatin when combined with another platinum, carboplatin.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Global MS analysis links disability burden to rising economic strain
2
New drug class shows promise for geographic atrophy
3
HS patients on biosimilar adalimumab lose response faster than those on the original drug
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5






















































